HPV infections and immune status in a cohort of girls who are eligible for national HPV immunization.

HPV infections and immune status in a cohort of girls who are eligible for national HPV immunization. - HPV infections and immune status

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54728

Enrollment

4229

Registered

2009-01-28

Start date

2009-03-05

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

human papillomavirus, immune response, vaccination

Interventions

bivalent HPV vaccination

Eligibility

Age

12 Years to 64 Years

Inclusion criteria

Inclusion criteria: female born in 1993/1994/2001 eligible for national HPV vaccination in 2009/2010/2014

Exclusion criteria

Exclusion criteria: pregnant vaccinated against HPV (only for birth cohorts in 1993/1994)

Design outcomes

Primary

Measure	Time frame
The main study parameters are:  - hrHPV DNA types 16/18 in vaginal self-sample  - Viral load in vaginal self-samples that are positive for HPV DNA type 16/18  - hrHPV-type specific antibody levels against HPV types 16/18 in serum	—

Secondary

Measure	Time frame
Further objectives are to obtain insight into the immune mechanism and presence of other HPV DNA types and antibodies against other HPV types:  - Level of HPV16/18 and possibly also other high risk HPV type specific immune cells, like T- and B-cells in blood  - HPV-16/18 IgG and possibly IgA antibodies present in serum and vaginal secretion  - Antibody levels against non-HPV16/18 types in serum and vaginal secretion  - Non-HPV 16/18 DNA types in vaginal self-sample  - Methylation of tumor suppressor genes, such as CADM1 and MAL for HPV 16/18 and for other hrHPV types  - HPV (L1, whole genome) sequence diversity between girls.  - Immune parameters ? Microbiota and mycobiota status	—

Measure

Time frame

Further objectives are to obtain insight into the immune mechanism and presence of other HPV DNA types and antibodies against other HPV types:  - Level of HPV16/18 and possibly also other high risk HPV type specific immune cells, like T- and B-cells in blood  - HPV-16/18 IgG and possibly IgA antibodies present in serum and vaginal secretion  - Antibody levels against non-HPV16/18 types in serum and vaginal secretion  - Non-HPV 16/18 DNA types in vaginal self-sample  - Methylation of tumor suppressor genes, such as CADM1 and MAL for HPV 16/18 and for other hrHPV types  - HPV (L1, whole genome) sequence diversity between girls.  - Immune parameters ? Microbiota and mycobiota status

—

Countries

Netherlands

Contacts

Public ContactH.E. de Melker

RIVM

info@rivm.nl088 689 8989

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)